AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01177722 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-Hep B-IPV vaccine
Description: 0.5 mL, Intramuscular
Study NCT02870699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evonail
Description: film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
Study NCT02870699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evonail
Description: film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
Study NCT02870699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo excipient
Description: film forming excipient solution
Study NCT02870699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo excipient
Description: film forming excipient solution
Study NCT03972007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fotobiomodulation
Description: A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
Study NCT03972007 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fotobiomodulation
Description: A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
Study NCT02082236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Arm A: Sufenta®
Description: Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
Study NCT02082236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Sufentanil SSM 30 mcg
Description: single-dose SSM 30 mcg
Study NCT02082236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: SSM 15 mcg
Description: 2 consecutive doses of SSM 15 mcg administered 20 minutes apart
Study NCT02082236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: SSM 30 mcg
Description: 12 consecutive doses of SSM 30 mcg administered 1 hour apart
Study NCT01688414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photoacoustic imaging
Description: Undergo PAI
Study NCT01688414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence imaging
Description: Undergo fluorescence imaging
Study NCT01688414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo robot-assisted laparoscopic surgery
Study NCT03998254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V503
Description: 9vHPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
Study NCT03998254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: qHPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
Study NCT02926131 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: * One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~* An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system
Study NCT02411682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast eating (YesB)
Description: On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
Study NCT02411682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast eating (YesB)
Description: On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
Study NCT02411682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast skipping (NoB)
Description: On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
Study NCT02411682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast skipping (NoB)
Description: On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
Study NCT00594126 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imetelstat Sodium (GRN163L)
Description: 25% dose escalation infused over 2 hours weekly
Study NCT03023228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetes self-management education
Description: 1-group, pre-test/post-test design feasibility and preliminary efficacy evaluation of diabetes survival skills self-management education delivered at the hospital bedside.
Study NCT04334733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon group
Description: The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process.
Study NCT04334733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaleidoscope group
Description: The children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
Study NCT04334733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon+Kaleidoscope group
Description: The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process and then the children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
Study NCT03478150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zinc oxide nano-particles
Description: The zinc oxide nano-powder will be mixed with ethanol
Study NCT03478150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser diode
Description: The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. the output power will be adjusted at 1.5W.
Study NCT02235974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intensive upper extremity motor training
Description: Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
Study NCT02235974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-acute intensive upper extremity motor training
Description: Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
Study NCT02235974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic intensive upper extremity motor training
Description: Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
Study NCT02235974 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual and Customary Care only. No additional therapy will be given during the 1-year study.
Study NCT01322048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Propranolol and Per Tube Clonidine
Description: 1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
Study NCT01322048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV q6h and Per Tube q12, both for 7 days
Study NCT00047203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00679588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin Sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study NCT00679588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study NCT00679588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Study NCT00679588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection
Study NCT00233805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus coated Bx Velocity™
Description: drug-eluting stent
Study NCT00233805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal Bx Velocity™
Description: bare-metal stent
Study NCT02466438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Description: * Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~  * Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~ * Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~* Acute Kidney injury : Dosing as prescribed by treating physician
Study NCT00846339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: bupropion
Study NCT04209699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Single dose
Study NCT04209699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose
Study NCT00561496 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir gel
Description: Intravaginal (4grams)single dose followed by fourteen days
Study NCT00647322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of anti-epileptic medications
Description: Reduction in anti-epileptic medications
Study NCT00647322 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No drug change
Description: No change in anti-epileptic treatment
Study NCT01257789 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic gastric bypass
Description: laparoscopic gastric bypass
Study NCT04461808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: tomosynthesis + synthetic 2D
Description: Women will be screened for one round with tomosynthesis + synthetic 2D, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography.
Study NCT04461808 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: digital mammography
Description: Women will be screened for one round digital mammography, two projections, double reading with consensus or arbitration, according to local protocols, for discordant readings.~After two years (one years for women 45-49 yo) women will be re-screened with digital mammography.
Study NCT00300781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Study NCT00909792 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B
Description: Silicone hydrogel, soft, multifocal contact lens
Study NCT00909792 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A
Description: Silicone hydrogel, soft, multifocal contact lens
Study NCT05188326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza 100 milligram (mg) injection
Description: 1st cycle 50 mg/sqm s.c. or i.v. for 7 days (5 + weekend off + 2) every 28 days and increase dosing after 1st cycle, if well tolerated, to 75 mg/ m2 for further 5 cycles, followed by cycles every 56 days for 4 years and six months post-remission.
Study NCT05188326 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Best supportive care includes antibiotics, transfusions and fluids
Study NCT02284048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ticagrelor
Description: compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
Study NCT02284048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
Study NCT00719563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American ginseng
Description: Given orally
Study NCT00719563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01868113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled corticosteroid
Description: Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
Study NCT01868113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered 12hourly
Study NCT01141348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Intervention
Description: 16 week behavioral weight loss intervention included 2 hour weekly group sessions
Study NCT01141348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Intervention
Description: During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
Study NCT02781272 — intervention group
Intervention type: PROCEDURE
Intervention: Pelvic imaging
Description: Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
Study NCT02781272 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
Study NCT02781272 — intervention group
Intervention type: PROCEDURE
Intervention: Imaging guided biopsy, surgical biopsy or surgical excision
Description: Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
Study NCT02700204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay 532nm fractional treatment
Description: is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
Study NCT02700204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay 1064nm fractional treatment
Description: is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
Study NCT01856166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Release analgesia by CADD SMITHS PCEA pump
Description: Analgesia will be release by continuous manner with an automatic pump
Study NCT01856166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Release analgesia by CADD SMITHS PIEB pump
Description: Analgesia will be release by bolus with an automatic pump
Study NCT01856166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Study NCT01856166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Study NCT01856166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Study NCT01856166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Study NCT02823756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Exercise, education, spinal manipulation
Study NCT03224325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Tablet T2
Description: Tak-831 tablets.
Study NCT03224325 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: TAK-831 placebo-matching suspension.
Study NCT03224325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 Suspension
Description: TAK-831 Suspension.
Study NCT03259594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic deroofing
Description: The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
Study NCT03259594 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic deroofing
Description: The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
Study NCT03259594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 g of amino acids supplementation
Description: intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
Study NCT03259594 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 100 g of amino acids supplementation
Description: intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
Study NCT00849719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a combination of PCA MO and continuous infusion of MO
Description: Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
Study NCT00849719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA MO only
Description: When visual analog scale \[VAS\] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
Study NCT00474669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
Study NCT01012843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanate
Description: oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days
Study NCT01012843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral Placebo tablets two times a day for 10 days
Study NCT01774851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-111
Description: MM-111 (IV)
Study NCT01774851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV)
Study NCT01774851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (IV)
Study NCT01774851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (IV)
Study NCT01774851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab (IV)
Study NCT02762825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: HIIT will consist of 4 min of higher intensity work set at 90% of heart rate reserve, based on peak heart rate from CPX test. Recovery intervals will be 3-4 min in duration and set at 60-70% of heart rate reserve. Resistance training will be performed once per week.
Study NCT02762825 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MCT
Description: MCT will consist of aerobic exercise performed 3 times per week for 30 min each session, at an intensity of 60-80% of heart rate reserve, based on peak heart rate from CPX test.
Study NCT02183636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/pioglitazone, FDC formulation C5
Description: film coated tablet (5 mg/45 mg)
Study NCT02183636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/pioglitazone, FDC formulation C8
Description: film coated tablet (5 mg/45 mg)
Study NCT02183636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin tablet
Description: 5 mg
Study NCT02183636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone tablet (Actos®)
Description: 45 mg
Study NCT02354898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Study NCT02354898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg twice daily (800mg total daily dose)